3 Horrendous Health-Care Stocks This Week: Impax Laboratories Inc (IPXL), Depomed Inc (DEPO), AngioDynamics, Inc. (ANGO)

Page 2 of 2

What’s next for Depomed Inc (NASDAQ:DEPO)? The company has pulled the plug on all spending on Sefelsa in treating hot flashes for now. However, it continues to sell the drug under the brand name Gralise for managing postherpetic neuralgia. Depomed Inc (NASDAQ:DEPO) also sells anti-inflammatory drug Zipsor and diabetes drug Glumetza, which partner Santarus, Inc. (NASDAQ:SNTS) markets in the United States.

None of the above
I normally attempt to pick the best of the horrendous health-care stocks of the week, but this week I must admit that I’m stumped. It’s hard to have much confidence in Impax Labs after failing an FDA inspection for the second time with three repeat issues.

AngioDynamics’ woes could be only temporary, but I’d prefer to take a wait-and-see stance. As for DepoMed, I’m not overly concerned about the FDA decision on Sefelsa. However, the company’s financial performance continues to be worrisome. My pick this week, therefore, is none of the above.

The article 3 Horrendous Health-Care Stocks This Week originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights and The Motley Fool have no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.



Page 2 of 2